Back to top
more

Sage Therapeutics (SAGE)

(Real Time Quote from BATS)

$12.69 USD

12.69
305,497

+0.40 (3.26%)

Updated Jul 22, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Why Sage Therapeutics (SAGE) Stock Might be a Great Pick

by Zacks Equity Research

Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Proteostasis (PTI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Why Earnings Season Could Be Great for Sage Therapeutics (SAGE)

by Zacks Equity Research

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.

Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Intellia (NTLA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

Guardant Health (GH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.

Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.

What's in Store for Aimmune (AIMT) This Earnings Season?

by Zacks Equity Research

Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.

Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.

What's in Store for Corcept (CORT) This Earnings Season?

by Zacks Equity Research

During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

by Zacks Equity Research

The biotech sector witnesses pipeline updates from the annual ASH meet.

Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher

by Zacks Equity Research

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

Sage Therapeutics' Depression Drug Fails in Study, Stock Down

by Zacks Equity Research

Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.

VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints

by Zacks Equity Research

VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.

Kinjel Shah headshot

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Moving Average Crossover Alert: Sage Therapeutics

by Zacks Equity Research

Sage Therapeutics could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline

by Zacks Equity Research

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.